Related Experiment Video
Updated: Aug 6, 2026

05:52
Novel Mini-open Transforaminal Lumbar Interbody Fusion
Published on: June 6, 2025
Measuring Variability and Value of Single- and Two-Level Anterior Cervical Discectomy and Fusion Using Impact Scores
Aiyush Bansal1, Kenneth T Nguyen2, Kento Yamanouchi3
1Center for Neurosciences and Spine, Virginia Mason Medical Center, Seattle, WA.
Spine
|July 25, 2026
Summary
Intraoperative supply costs in anterior cervical discectomy and fusion (ACDF) vary by surgeon and procedure level. Interbody devices significantly impact costs, with biologics showing the most surgeon variability.
Area of Science:
- Spine surgery
- Health economics
- Medical device utilization
Background:
- Intraoperative supply costs in ACDF procedures exhibit significant variability, largely influenced by implant choices.
- Current cost data is institution-specific, hindering cross-site comparisons and benchmarking.
- Impact scores offer a normalized method to assess supply cost contributions, independent of institutional pricing.
Purpose of the Study:
- To quantify intraoperative supply cost variability among surgeons and procedural levels in ACDF.
- To evaluate within-procedure value using time-driven activity-based costing (TDABC), Operative Value Index (OVI), and Unit Price per Outcome (UPO).
Main Methods:
- Retrospective analysis of 369 ACDF cases (1- and 2-level) performed by five surgeons.
- Supply items were categorized to calculate impact scores (proportional cost share).
- TDABC estimated staff costs; Neck Disability Index (NDI) and quality-adjusted life year (QALY) were used to derive OVI and UPO.
Main Results:
- Interbody devices and plates constituted the highest cost categories in both 1- and 2-level ACDF.
- Interbody implant costs significantly increased with surgical level (P<0.001).
- Biologic and interbody categories displayed the greatest inter-surgeon cost variability, with OVI and UPO varying over 2.5-fold.
Conclusions:
- Interbody devices are the primary cost drivers in ACDF, with costs escalating with additional surgical levels.
- Biologics demonstrate the most substantial variability in cost among surgeons.
- OVI and UPO provide valuable, institution-independent benchmarks for assessing procedural value.